Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Healthcare workers play a critical role in fighting the pandemic, not only by managing the patients' health clinically, but also by implementing adequate measures for infection prevention and control in healthcare facilities. This puts healthcare workers at a greater risk of acquiring the disease. COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) and many people can be infected with it asymptomatically and undetectably.
Serology is an antibody test that provides additional information to polymerase chain-reaction (PCR) testing as it is the only way to reliably establish the fraction of the population that was infected . Seroconversion is the development of antibodies in the blood which can confirm suspected cases after the fact and reveal who was infected but asymptomatic and never realized it. Antibodies are specific proteins created as the body's response to the infection and this test is essential for detecting infected individuals with few or no symptoms at all.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High-risk | Employees at high-risk of Coronavirus exposure areas (physicians, nurses, respiratory therapists, radiology technologists, lab technologists, housekeepers) |
| |
| Low-risk | Employees working at lower risk areas such as (administration, HR, Public relations) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Serology Test | Diagnostic Test | Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2). at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test. |
| Measure | Description | Time Frame |
|---|---|---|
| Seroconversion status | Percentage of health care workers with positive serological markers to describe patterns in exposure, re-infection, clinical symptom, serological responses among health care workers based on their baseline serological status over a one year period. | 6 Months |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of asymptomatic infections among staff who have seroconverted | Seroconversion without clinical manifestation (fever, body aches, headache, sweating, chills + respiratory symptoms (cough dyspnea, sputum) or digestive (nausea / vomiting diarrhea abdominal pain) | 6 Months |
| The durability of COVID 19 seroconversion in asymptomatic healthcare workers at JHAH |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Any participant exhibiting COVID 19 symptoms
Not provided
Not provided
Not provided
Healthcare workers, divided into two groups (High-risk and Low-risk).
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins Aramco Healthcare | Dhahran | Eastern Province | 31311 | Saudi Arabia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37283943 | Derived | Mushcab H, Al-Tawfiq JA, Babgi A, Ghamdi M, Amir A, Sheikh SS, Darwisheh A, AlObaid A, Masuadi E, AlFattani A, Qahtani S, Al Sagheir A. Longevity of Immunoglobulin-G Antibody Response Against Nucleocapsid Protein Against SARS-CoV-2 Among Healthcare Workers. Infect Drug Resist. 2023 May 31;16:3407-3416. doi: 10.2147/IDR.S400365. eCollection 2023. | |
| 35974896 |
| Label | URL |
|---|---|
| Coronavirus disease (COVID-19) technical guidance: The Unity Studies: Early Investigations Protocols | View source |
Not provided
We are willing to share our data after collection de-identified. We plan to share the data with WHO for their unity studies
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 9, 2022 | |
| Reset | Jul 6, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 9, 2022 | Jul 6, 2023 |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D018352 | Coronavirus Infections |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D012698 | Serologic Tests |
| ID | Term |
|---|---|
| D007159 | Immunologic Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
To identify the durability of antibody seroconversion |
| 6 Months |
| Identification of risk factors for COVID 19 seroconversion in asymptomatic healthcare workers | Age, gender, type of staff, resources | 6 Months |
| Mushcab H, Al-Tawfiq JA, Ghamdi M, Babgi A, Amir A, Sheikh SS, Darwisheh A, Alobaid A, Jebakumar AZ, Qahtani S, Al Sagheir A. A Cohort Study of Seroprevalence of Antibodies Against SARS-CoV-2 Infection Among Healthcare Workers at a Tertiary Hospital in Saudi Arabia. Infect Drug Resist. 2022 Aug 10;15:4393-4406. doi: 10.2147/IDR.S369755. eCollection 2022. |
| D014777 |
| Virus Diseases |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D008919 | Investigative Techniques |
| D007158 | Immunologic Techniques |